Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831793 | 0.91 | BACE1 (0.48) | BACE1S1PR1 | |
| SCHEMBL831254 | 0.91 | BACE1 (0.50) | BACE1S1PR1 | |
| SCHEMBL829464 | 0.91 | BACE1 (0.50) | BACE1S1PR1CA2 | |
| SCHEMBL4078824 | 0.91 | BACE1 (0.50) | BACE1S1PR1 | |
| SCHEMBL16493931 | 0.89 | BACE1 (0.48) | BACE1CA2 | |
| SCHEMBL16493930 | 0.89 | BACE1 (0.48) | BACE1S1PR1CA2 | |
| SCHEMBL5586128 | 0.85 | BACE1 (0.55) | BACE1 | |
| SCHEMBL832970 | 0.85 | BACE1 (0.55) | BACE1 | |
| SCHEMBL5586129 | 0.85 | BACE1 (0.55) | BACE1 | |
| SCHEMBL16493658 | 0.85 | BACE1 (0.45) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2077719-B1 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | BACE1 1/4885S1PR1 507/4885CA2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.